Merrill D P, Moonis M, Chou T C, Hirsch M S
Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
J Infect Dis. 1996 Feb;173(2):355-64. doi: 10.1093/infdis/173.2.355.
Two- and three-drug combinations of lamivudine or stavudine with other antiretroviral drugs were evaluated for activity against human immunodeficiency virus type 1 (HIV-1) activity in peripheral blood mononuclear cells. Other agents included zidovudine, didanosine, nevirapine, and saquinavir. Paired zidovudine-sensitive and -resistant clinical HIV-1 isolates were used. Additive or synergistic interactions were observed against the zidovudine-sensitive isolate with the following combinations: lamivudine-zidovudine, lamivudine-stavudine, lamivudine-saquinavir, lamivudine-nevirapine, stavudine-zidovudine, stavudine-didanosine, stavudine-saquinavir, stavudine-nevirapine, lamivudine-zidovudine-saquinavir, lamivudine-zidovudine-stavudine, stavudine-zidovudine-nevirapine, lamivudine-zidovudine-nevirapine, and stavudine-zidovudine-saquinavir. Against the zidovudine-resistant isolate, additive or synergistic interactions were seen with most two- and three-drug combinations, but the combination of stavudine-zidovudine was antagonistic. The clinical implications of these in vitro observations should be explored.
对拉米夫定或司他夫定与其他抗逆转录病毒药物的二联和三联组合进行了评估，以检测其对外周血单核细胞中1型人类免疫缺陷病毒（HIV-1）的活性。其他药物包括齐多夫定、去羟肌苷、奈韦拉平和沙奎那韦。使用了配对的齐多夫定敏感和耐药的临床HIV-1分离株。观察到以下组合对齐多夫定敏感分离株有相加或协同相互作用：拉米夫定-齐多夫定、拉米夫定-司他夫定、拉米夫定-沙奎那韦、拉米夫定-奈韦拉平、司他夫定-齐多夫定、司他夫定-去羟肌苷、司他夫定-沙奎那韦、司他夫定-奈韦拉平、拉米夫定-齐多夫定-沙奎那韦、拉米夫定-齐多夫定-司他夫定、司他夫定-齐多夫定-奈韦拉平、拉米夫定-齐多夫定-奈韦拉平以及司他夫定-齐多夫定-沙奎那韦。对于齐多夫定耐药分离株，大多数二联和三联组合显示有相加或协同相互作用，但司他夫定-齐多夫定组合具有拮抗作用。应探讨这些体外观察结果的临床意义。
